Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure.

Published

Journal Article

BACKGROUND: In patients with acute heart failure, early intervention with an intravenous vasodilator has been proposed as a therapeutic goal to reduce cardiac-wall stress and, potentially, myocardial injury, thereby favorably affecting patients' long-term prognosis. METHODS: In this double-blind trial, we randomly assigned 2157 patients with acute heart failure to receive a continuous intravenous infusion of either ularitide at a dose of 15 ng per kilogram of body weight per minute or matching placebo for 48 hours, in addition to accepted therapy. Treatment was initiated a median of 6 hours after the initial clinical evaluation. The coprimary outcomes were death from cardiovascular causes during a median follow-up of 15 months and a hierarchical composite end point that evaluated the initial 48-hour clinical course. RESULTS: Death from cardiovascular causes occurred in 236 patients in the ularitide group and 225 patients in the placebo group (21.7% vs. 21.0%; hazard ratio, 1.03; 96% confidence interval, 0.85 to 1.25; P=0.75). In the intention-to-treat analysis, there was no significant between-group difference with respect to the hierarchical composite outcome. The ularitide group had greater reductions in systolic blood pressure and in levels of N-terminal pro-brain natriuretic peptide than the placebo group. However, changes in cardiac troponin T levels during the infusion did not differ between the two groups in the 55% of patients with paired data. CONCLUSIONS: In patients with acute heart failure, ularitide exerted favorable physiological effects (without affecting cardiac troponin levels), but short-term treatment did not affect a clinical composite end point or reduce long-term cardiovascular mortality. (Funded by Cardiorentis; TRUE-AHF ClinicalTrials.gov number, NCT01661634 .).

Full Text

Duke Authors

Cited Authors

  • Packer, M; O'Connor, C; McMurray, JJV; Wittes, J; Abraham, WT; Anker, SD; Dickstein, K; Filippatos, G; Holcomb, R; Krum, H; Maggioni, AP; Mebazaa, A; Peacock, WF; Petrie, MC; Ponikowski, P; Ruschitzka, F; van Veldhuisen, DJ; Kowarski, LS; Schactman, M; Holzmeister, J; TRUE-AHF Investigators,

Published Date

  • May 18, 2017

Published In

Volume / Issue

  • 376 / 20

Start / End Page

  • 1956 - 1964

PubMed ID

  • 28402745

Pubmed Central ID

  • 28402745

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1601895

Language

  • eng

Conference Location

  • United States